At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VIRX Viracta Therapeutics, Inc.
Closed 11-14 16:00:00 EST
0.1579
+0.0008
+0.51%
盘后0.1633
+0.0054+3.42%
19:28 EST
High0.1695
Low0.1500
Vol333.68K
Open0.1695
D1 Closing0.1571
Amplitude12.41%
Mkt Cap6.22M
Tradable Cap3.91M
Total Shares39.42M
T/O53.30K
T/O Rate1.35%
Tradable Shares24.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
RBC Cuts Price Target on Viracta Therapeutics to $2 From $4, Keeps Outperform, Speculative Risk
Viracta Therapeutics Q3 2024 GAAP EPS $(0.27) Misses $(0.24) Estimate, Cash, Cash Equivalents, And Short-term Investments Of Approximately $21.1M Is Expected To Fund Operations Late Into The First Quarter Of 2025
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-Val Development Program in Patients With Relapsed or Refractory Ebv-Positive Peripheral T-Cell Lymphoma
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.